An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Reason given: Replaced it with another clinical trial
Key facts
- Where
- Allentown, Aurora, Bakersfield, Boston, Chapel Hill, Charlotte, Daphne, Fargo, Fullerton, Lakewood, Los Angeles, Marietta, Miami, New Brunswick, Redondo Beach, Santa Barbara, Sioux Falls, St Louis, Tampa, and Vancouver, United StatesSee the 20 sites
- Phase
- Phase 2
Where in United States
- AllentownAllentown, United StatesNo longer taking part
- AuroraAurora, United StatesNo longer taking part
- BakersfieldBakersfield, United StatesNo longer taking part
- BostonBoston, United StatesNo longer taking part
- Chapel HillChapel Hill, United StatesNo longer taking part
- CharlotteCharlotte, United StatesNo longer taking part
- DaphneDaphne, United StatesNo longer taking part
- FargoFargo, United StatesNo longer taking part
- FullertonFullerton, United StatesNo longer taking part
- LakewoodLakewood, United StatesNo longer taking part
- Los AngelesLos Angeles, United StatesNo longer taking part
- MariettaMarietta, United StatesNo longer taking part
- MiamiMiami, United StatesNo longer taking part
- New BrunswickNew Brunswick, United StatesNo longer taking part
- Redondo BeachRedondo Beach, United StatesNo longer taking part
- Santa BarbaraSanta Barbara, United StatesNo longer taking part
- Sioux FallsSioux Falls, United StatesNo longer taking part
- St LouisSt Louis, United StatesNo longer taking part
- TampaTampa, United StatesNo longer taking part
- VancouverVancouver, United StatesNo longer taking part
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT03704077
- Record updated
- 19 May 2020
- Original description
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.Read full original descriptionShow less
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Inclusion: Histologically or cytologically confirmed locally advanced or recurrent or metastatic GC or GEJ adenocarcinoma that is considered incurable by local therapies such as radiation or surgery; Evidence of progressive disease (PD) on at least one prior platinum- and fluoropyrimidine-containing chemotherapy regimen; Available tumor tissue for biomarker analysis.
Exclusion: Uncontrolled or significant cardiovascular disease; Other protocol defined inclusion/exclusion criteria could apply; Must not have squamous cell or undifferentiated GC or GEJ; Untreated known central nervous system (CNS) metastases.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.